No Data
No Data
BTIG Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $8
BTIG analyst Mark Massaro maintains $MDxHealth(MDXH.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 29.4% and a total
Strong Buy Rating for MDxHealth: Robust Revenue Growth and Strategic Value Proposition
MDxHealth Jumps 7% on Raising FY 2024 Guidance
Express News | MDxHealth Raises FY24 Revenue From $83M-$85M To $85M-$87M Vs $84.048M
Express News | MDxHealth Sees Prelim Q2 Revenue ~$22.2M Vs $20.214M Est
MDxHealth Sees 2024 Rev $85M-$87M >MDXH
MDxHealth Sees 2024 Rev $85M-$87M >MDXH
No Data
全力買い : Do you have bio recommendations?